Treatment Characteristics |
Estimates |
Remission |
45 out of 100 patients go into remission |
25 out of 100 patients go into remission |
15 out of 100 patients go into remission |
Improvement |
70 out of 100 patients feel much better, but occasionally have some joint pain or swelling |
50 out of 100 patients feel much better, but occasionally have some joint pain or swelling |
40 out of 100 patients feel much better, but occasionally have some joint pain or swelling |
Radiographic progression |
No further bone damage seen on X-rays in 80 out of 100 patients |
No further bone damage seen on X-rays in 50 out of 100 patients |
No further bone damage seen on X-rays in 30 out of 100 patients |
Route |
Pill you take once a week |
Injection you give yourself once every 1-2 weeks |
Intravenous infusion you get every 6-8 weeks |
Injection reaction |
No injection reactions |
30 in 100 patients get a rash or local burning at the site of injection |
3 in 100 patients will get a reaction during the infusion (headache, nausea, fever) |
Reversible adverse events |
No increased risk of nausea, dizziness or unusual tiredness |
10 in 100 people will have nausea, dizziness or unusual tiredness |
Risk of lung injury |
No increased risk of lung or liver injury |
Rare risk of lung injury (about 2 in 100 patients) or liver injury (about 1 in 1000 patients) |
Risk of tuberculosis |
No increased risk of tuberculosis |
Extremely rare risk of tuberculosis (about 1 in 10,000 patients) |
Extremely rare adverse events |
No increased risk of neurologic disease or heart failure |
Extremely rare risk of neurologic disease or heart failure (about 1 in 10,000 patients) |
Risk of cancer |
No increased risk of cancer |
Possible increased risk of cancer (about 1 in 1000 patients) |